Floatz logo

Prgn-3005 Ultracar-T Cells

Platinum-Resistant Ovarian Carcinoma

Precigen, IncCell therapyPhase 1Active
CC
43/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
28/ 100
Competitive Position
89/ 100

Competitive context

244 Active assets in the Platinum-Resistant Ovarian Carcinoma cohort.

Asset / SponsorPhaseRating
Mirvetuximab Soravtansine
AstraZeneca
Phase 3BBB
Trabectedin
AGO Research GmbH
Phase 4BBB
Irinotecan
OHSU Knight Cancer Institute
Phase 2BB
Olaparib
Imunon
Phase 4BB
Carboplatin
University of Washington
Phase 3BB

View all 50 →

Same molecule, other indications

Prgn-3005 Ultracar-T Cells is also rated in:

fallopian tube carcinomaDormant
CC
Indicative ·
43 / 100
View asset →
primary peritoneal carcinomaDormant
CC
Indicative ·
43 / 100
View asset →
fallopian tube cancerDormant
CC
Indicative ·
43 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →